ACR 2026: Interstitial Lung Disease Topic Panel
What stood out in interstitial lung disease (ILD) at ACR 2026? Join Drs. Jack Cush, Elena Joerns, Janet Pope, and Daric Mueller, PA-C for RheumNow’s ILD Topic Panel Recap. The panel highlights research from Orlando and discusses what the findings could mean for rheumatologists caring for patients with ILD.
Abstracts:
1617 Substudy of Fibroneer
0645 2 yr outcomes of myositis-ILD
0025 Biomarkers
1586 Myositis ILD
2914 Substudy myositis ILD in Fibroneer
0430 Sjogren's ILD
2882 AutoAbs in RA-ILD
Transcription
Let's begin with introductions. I'm Jack Cush in Dallas, Texas. Janet — Janet Pope, London, Ontario, Western University. And Daric — hey everyone, Daric Mueller, PA, Detroit, Michigan. And Elena — hi, Elena Joerns, Rochester, Minnesota.
Okay, let's begin with Elena. What did you find to be really interesting last week at ACR? Yeah, so there were quite a few interesting abstracts. So the first one I wanted to talk about was a subgroup analysis of the myositis in the FIBRONEER trial. So again, that's a trial of nerandomilast, which is a PDE4B inhibitor, in ILD, and they had a subgroup of autoimmune patients and 33% was myositis. So they were looking at whether there was any signal in those patients with administration of nerandomilast either at 18 milligrams or 9 milligrams, and they did find that there was a signal — there was much less decline in FVC after — at the end of the trial in the 18 milligram group, and also a sizable less decline in the 9 milligram group, and the extent of the decline was better in the higher dose group. So that is very encouraging. Both of those confidence intervals cross zero, so we cannot really make specific conclusions, but it does look encouraging for the patients with myositis.
And then another study that I wanted to talk to you guys about is abstract 0430. So that was looking at a study out of Brazil that looked at characteristics of Sjögren's-associated ILD. So there were a couple of interesting things about that abstract. They had 118 patients with primary Sjögren's and all of them underwent chest CT. They found actually that 46 of them had ILD, which is like 44%. So one, their ILD was very common in Sjögren's, which surprised me. Of course it was a retrospective study, so it could have been higher because they underwent chest CTs. And then they found that older age was associated with higher odds of ILD, but low C4 and parotid involvement, and also it looked like cryoglobulinemia were all associated with lower odds of ILD. So they were kind of thinking that maybe there's a different mechanism that is causing the ILD in Sjögren's — not this classically B-cell-driven mechanism.
So I want to ask first about the myositis report. I've been impressed by a lot of the literature and its association with many autoimmune diseases — scary poor outcomes — but that's why we have this major trend right now to research this, study this, develop new drugs for this, and all that's good. If there's a subgroup that looked good, it looked like it's the myositis group. And did that show up in this trial, or were the people that were severe enough to get into the FIBRONEER study so severe — were those associated with myositis — maybe better candidates, like you might have seen from other studies before?
Yeah. In this FIBRONEER study, they only included patients with progressive pulmonary fibrosis, which of course can sometimes be difficult in our diseases because — how are we defining progressive pulmonary fibrosis? Does it mean that they're not being treated adequately? So yes, there might be some selection bias with those patients. And also they weren't allowed a lot of background medications that we are seeing. So maybe we are seeing that any treatment was better than minimal treatment in those patients. It's hard to tell whether truly nerandomilast was adding benefit to these patients.
You know, I believe from the FIBRONEER study they didn't really see necessarily differences in signals between various autoimmune diseases, but all the numbers were so low. And of course there is a study that is going on right now — they recently actually completed recruitment — the FIBRONEER SARD, where they are focusing on patients who were stable or declining. So we might get a little bit more answers whether nerandomilast is truly helpful in addition to background immunosuppression and also whether it's helpful in patients who are not actively progressing.
Can you define SARD for our audience? Yes, SARD is a term introduced by ACR a couple years ago — Systemic Autoimmune Rheumatic Disease. So CTD is going out of fashion, folks. It's SARD in the ILD world. [laughter]
So Janet, you deal with a lot of this in your scleroderma work and studies. What do you look at with this data? Is it really encouraging, these subset analyses, or is it part of a bigger picture? Both actually. So first of all, I'm really excited about the whole FIBRONEER for our kind of progressive pulmonary fibrosis patients, because none of these are meant to look at the subset of the subset of the subset by a p-value, but to look — are things going in the right direction? And I think what has me most excited overall on nerandomilast in the progressive pulmonary fibrosis non-IPF patients — and other reasons for PPF that aren't IPF — is less hospitalizations, less time to clinical worsening, less bad outcomes. So I think it's pretty exciting. But if we go down down down on a subgroup of a subgroup of a subgroup kind of thing, if you don't get a p-value, don't worry about it. Just say, is the treatment consistent or not with what I would expect from the other SARDs etc. So I'm excited.
Yeah. Um, I want to go to that second report. I too was surprised by the amount of ILD that was found retrospectively — and maybe a little bit of a bias there — but I don't usually think about screening Sjögren's for ILD. Derek, what — you're interested in this area — how do you handle who you screen for?
Well, I think with Sjögren's it's a similar story to rheumatoid arthritis. Unless a patient has crackles or suggestive symptoms, it's not necessarily — I'm not going digging for it — just like with rheumatoid arthritis. You know, we're going to find interstitial lung abnormalities on many of these patients and we don't necessarily want to go digging that up if it's not something that's actionable, or if it's going to result in some potential nonsense with their therapy, like a drug being withdrawn that maybe should not have been. So I think there's a fine line in some of these diseases. I mean, I think certainly higher-risk groups in the myositis and systemic sclerosis definitely deserve much closer screening, but in Sjögren's I don't think anyone is too sure on that.
You know, I'd like to get off on this tangent because I think it's important for the audience. What we've learned in the last few years with EULAR guidelines and a bunch of guidelines on ILD and screening — we're supposed to be screening more patients. And the question is, are you going to be pragmatic like Derek and look for ILD in people who are either at high risk or people who are symptomatic where then an intervention makes sense — a new treatment makes sense — or should you screen and then make that a high-risk patient after you've seen there was an issue? There was an abstract at EULAR that said that if you screen all RA patients without symptoms, it was like 7% had ILD by high-res chest CT screening.
So Elena, you and Janet are really connected to this literature. I'd like to know your guidance for the audience on how we should be approaching screening. Yeah. So both ACR and EULAR kind of gave guidelines on who they consider high-risk patients for ILD in Sjögren's, and both of them state older age, but ACR also includes Ro-52, ANA, Raynaud's, severe dental caries, and also lymphopenia, and then EULAR lists elevated inflammatory markers and active extra-pulmonary involvement. So this study kind of showed a little bit different — kind of different factors — they didn't really find anything that was increasing the risk besides the older age.
Now, all of those guidelines really gave these recommendations not based on the risk to the patient necessarily, but more on the cost to the healthcare system. So for me, needs of the patients come first. And I see so much ILD that went bad — I will screen patients with Sjögren's most of the time, at least once.
Interesting. And by that you mean CT? As opposed to — I mean CT, yes. Janet, what's your approach? So my approach in Sjögren's is different than in scleroderma. In scleroderma — even myositis — I'm going to screen everybody. In Sjögren's I usually wait for signs or symptoms, and I realize that might be waiting till late. I listen to every SARD — I'll call them CTD, formerly — patient at every visit. Why not? It takes four seconds to listen for crackles. Yes or no? So it won't take much for me to investigate. But I must say, there is no way — even if I'm missing three-quarters — there is no way that Sjögren's has that high a rate that's clinically relevant. So I don't want to pick up stuff that we have to deal with and we don't know what to do with because they're asymptomatic and you don't know — is it old scar tissue? Obviously if it's progressing, that's one thing, but you know, people can have pneumonia and have a scar or something. So that's the way I would think, but I realize we do see different kinds of patients.
Yeah. I think this is important because we have to have a firm story in our head about what you're going to do with the results when you get them. Is it going to help you manage the patient in the long run? And again, better management of these patients could be a substantial savings to the patient, the family, and society in general.
Let's move on. Derek, let's hear your two abstracts that you thought were noteworthy from this meeting. All right. So the first is abstract 1617 by Bonella et al., and this is another subgroup analysis from that FIBRONEER trial of progressive pulmonary fibrosis. And I think it's important to look at this data in different ways because this is such a large population of SARD-ILD patients that I think it makes sense to sift through this — a lot of this is hypothesis-generating for sure and very interesting. So again, within the FIBRONEER ILD trial, which was a very large trial — over a thousand patients that included multiple forms of non-IPF ILD — our cohort of SARD patients made up about 325, most of it was either rheumatoid arthritis, systemic sclerosis, and then a smattering of myositis, mixed connective tissue disease, and what have you.
So this specific subgroup analysis was interested in looking at the time of initial diagnosis and if that made any kind of influence upon the efficacy of the intervention nerandomilast. So the subgroups looked at a couple different categories: diagnosis of equal to or less than a year, 1 to 3 years, 3 to 5 years, and then 5 years plus — roughly busted up into quarters in each of those groups. Within the subgroup analysis it did not appear that time since diagnosis had any obvious detriment to the trend in FVC decline, exacerbation risk, hospitalization, or death. So a lot of things we care about — but with all the caveats of a subgroup analysis. I think this is very interesting for understanding and appreciating that it might not be too late to use these drugs. They may have a role to play early on in the course of ILD and then potentially later on. But of course we're potentially grappling with a different ratio of active inflammation to fibrosis depending on what disease we're looking at and what time period they were diagnosed.
So the time to diagnosis was relative to their primary SARD diagnosis — like relative to how many years into RA before they developed ILD. Is that what that was? I believe it was actually the time to ILD within that rheumatic diagnosis, not necessarily since the diagnosis of RA, if I'm making sense there. Okay. So I'm just wondering — does that translate to trajectory or rapidity of disease? I don't know that it does, because I think that is an important factor — how rapidly you change with your ILD has a lot to do with morbidity and mortality — but I don't know that this one captures that. I think it does make the point that treatment may be appropriate at different time points.
Janet, what do you think? I agree. I think it's difficult — not everything's cut and dry. So all purely fibrotic honeycombing and no ground glass is probably — well, we know it's progressive pulmonary fibrosis, but it might not be as amenable, in addition to the PPF treatment, to immunosuppression, whereas NSIP — really quite inflamed, the way some of our acute myositis patients are — is probably very responsive in many to immunosuppression. But I think there's a whole bunch of in-betweens, and so therefore I agree that there's probably a season or a time to treat with sometimes both, or treat with one and add the other one quickly, depending on what direction you're going. And I don't think that imaging is as black and white — pun intended — as we think it might be.
Elena, do you have a comment on this? My question to you is — we're considering response to nerandomilast based on having an autoimmune disease and also the time to diagnosis. Is it right to do that by diagnosis, or should we be considering responsiveness according to pathology — whether they're UIPs or NSIPs or otherwise, including mixed pictures? Yeah, you know, that's a great question. There were a number of abstracts at the meeting that really indicated that RA — even UIP — needs to be treated with immunosuppression, would be amenable to immunosuppression. So I think autoimmune UIP is a different beast than some of the other UIPs that we might encounter. So it might be okay — actually, I think it is appropriate to do it by diagnosis because we are seeing more and more that it matters, in terms of — I mean, the end result might look similar on imaging or what have you, but how they're getting there and maybe even the processes that are continuing might be different.
I will say also it's good to kind of know when the nerandomilast was started. We so frequently are wondering — at what point should we add something? Should this be a stepwise therapy? Should we be throwing everything at the patients at the same time? And I think if we can answer that question with our studies, that would be very clinically useful.
Okay. Derek, what was your second one? Second one was abstract 0645 by Jones et al. So this was looking at mortality from time of idiopathic inflammatory myopathy diagnosis associated with ILD. So it was a relatively small cohort out of Vanderbilt of 41 patients newly diagnosed with myositis-ILD and looking at specific outcomes over a two-year period. At baseline, 43% of these patients were on supplemental oxygen. Many of them were hospitalized. So this was a relatively sick cohort of patients. Looking at two-year outcomes, 15% of patients died in the two-year follow-up period at a median time of 8.5 months. 9.8% of these patients required lung transplantation, and that occurred around 13 months. But a smaller portion of the patients who survived — only 13.3% of survivors had progression — while half of the survivors actually had improvement, and improvement in their cohort was greater than 10% predicted FVC. And it looked like all these patients who were survivors benefited from immunotherapy of whatever was selected in this observational cohort, and there were improvements regardless of what their baseline oxygen status was, if they required supplemental or not.
So I think this agrees with what we know about myositis — that a lot of times the severe cases are front-loaded. These patients usually require aggressive management up front, but the people who do seem to respond to therapy, there is improvement and there is the chance for survival and long-term improvement.
Do we know what the autoantibody profile was — how many of those were MDA5s? It was not cited in the abstract. That's definitely information I would like to know. But yes, we don't know the MDA5s, the anti-synthetase — not in this abstract that I saw.
So my question to all of you then is — is this typical of myositis-associated ILD? My eyes got big with the numbers — 15% getting worse, 9% death and transplant — that's 24% doing really badly. When I started out by saying if there's a subgroup of ILD that might do well, it might be the myositis people, but maybe there's a subset within myositis that's going to do really poorly, but there's a lot that can turn around. So how should I read this? Elena, what do you think?
I mean, I think there was definitely selection bias — most of these patients were already very very sick at baseline. I see a lot of cases where if we can catch them and we can immunosuppress them — I would say this sounds about right for those really sick patients at baseline. But I haven't heard what kind of immunosuppression they were on. I just heard immunosuppression. I don't know if they provided that detail, Derek, but yeah, this is — I would say this is pretty typical, and a lot of times these people require triple or quadruple therapy up front to stabilize them.
Is this what you see too? It is, unfortunately. So early — great for a lot of them, they're caught early, they're treated fairly aggressively. Steroids and — I agree — triple therapy if they have really quite obvious either MDA5 or quite obvious anti-synthetase at the beginning. The problem is some of these people get over that hump and smolder, and years later — not necessarily MDA5 but Jo-1, other synthetase, etc., Ro-52 — and later they become — I'll call it far higher mortality risk on their lungs — where almost like it got away from me under the radar screen. Yeah.
All right. That's really important. Janet, you had a few that you wanted to talk about. Go right ahead. Right. So the first one — I'm going to change the order of what I'll talk about — because abstract 1586 is yet another myositis, dermatomyositis with ILD. So this is a study looking at — I'll call it hypothesis-generating, probably not hypothesis-testing — because the VALOR-VO study was breidnib — and to remind people, that was a positive phase 2-to-3 RCT in dermatomyositis. And brepocitinib — they call it TYK2/JAK1 but I would like to say JAK1/TYK2 because that's how all the other terminology is — so maybe they're stressing it's more TYK2 than JAK. I don't know. But anyway, it's a TYK2/JAK1 drug.
So the phase 2-3 study had 241 people with dermatomyositis and of that, 20% or 47 people had baseline ILD. Now, if you're really severe you probably wouldn't put someone in a placebo-controlled trial because you're failing background immunosuppression. So we'll call it ILD that they're bad enough to get in a trial but maybe not the most severe. However, this is a 52-week study. What happens? Either on 15 milligrams of brepocitinib you get 1% improvement over a year in FVC — so probably stable to no change — on 30 milligrams, same thing, 0% change. But placebo in only one year went down by a mean FVC of 3% predicted. And you go — 3%, no big deal — but it is, that means some people would have met criteria for rapid progression. We don't have all the results, but I think that this is something that makes me interested to say, you know, this might be a really good drug. We've had a lot of ideas of JAK inhibitors helping in some patients, but no RCT looking specifically at ILD. And let's be fair, this is only 47 patients, a subset analysis, but I think there might really be something there — so that's why I chose it.
Yeah, I think this is novel. You know, the VALOR study was published in the New England Journal this past summer. I believe in the United States this drug is poised for FDA approval sometime in the very near future, and it would join IVIG as one of the few approved therapies for myositis — in this case dermatomyositis. So I think this is really exciting. And the question is, how is our treatment algorithm going to change for myositis? I think this kind of information might make you want to go down this path as opposed to using methotrexate. I mean, one of my favorite drugs in dermatomyositis/polymyositis is leflunomide — also implicated in causing ILD. I don't believe that methotrexate causes ILD but you don't want to give those drugs when you've got a lung thing on the table. Maybe you're jumping more to IVIG and a JAK1/TYK2 drug.
Derek, what do you think of this data? Well, I think something to keep in mind with this trial too is that patients could still be on background immunosuppression. So if a patient was on mycophenolate, they could continue their mycophenolate. If they were on methotrexate, they could continue methotrexate. So I think this data is important because it also tells us a little bit on the side that we're combining these drugs and it's potentially efficacious — that gives us some information about the safety of doing that. I don't think the subgroup analysis necessarily looked at who was on more agents than that, but I think that's an important takeaway too — there's a lot of combination therapy going on in this myositis population.
So this goes a little bit to your point about in some of these subsets like myositis, there's a role for immunosuppression, especially early on. What do you think? Yeah, I absolutely agree. And in terms of how it changes the algorithm — I believe it's already approved, because I put a patient on it just recently. And I'm glad to see these results, specifically for ILD, because that's kind of what the goal is for me most of the time — to treat the ILD along with other manifestations in the patient. So I think it will change the way that we approach these patients definitely, and that can only be a good thing.
Janet, what was your second one? Okay, so this one — sometimes people start snoozing when I talk about biomarkers — but I'm going to tell you the results and I'm going to tell you why I chose them. So this was poster 0025. This was an abstract that looked at accelerated senescence being increased in SARD patients, and they also looked at whether — because it's hard to know in the time frame that they looked — it could also be that if you have high senescence changes that you could have more progression to fibrotic lung disease. And what it showed — this was a basic science kind of study — there's epithelial remodeling that's negative, it's not helpful, and it's from DNA damage. So this senescence was far higher in the lung biopsies and stuff like that in SARD patients than, say, a lung that was looked at for a different reason.
So now I'm going to tell you why I looked at this — because I had a meeting with a lot of pulmonologists there and they were talking about short telomeres, and that is apparently a really big deal as a risk in maybe one in ten patients with IPF, and I didn't really know anything about that. I knew that lots of our diseases could have accelerated aging. So it kind of took me down a rabbit hole to look at what data are there on progression of NSIP in our patients — or a non-fibrotic phenotype into a fibrotic phenotype — and a lot of the risk factors, depending on the disease — high CRP for instance etc. — are also elevated when a patient seems to be transitioning. I say "seems to be" because it's not overnight; you don't do a CT every day, it might be over a year. But high — some of the antibodies associated with ILD in each disease are also associated with more progression to fibrosis. Same with CRP and same with a few other markers that we don't look at that often.
So I thought the senescence thing might kind of help tie it together — if things were readily available, would I be the one to order them on my patients to say — I lose sleep over you at night, I wouldn't tell them that way, but should I worry about you or shouldn't I worry about you? So it's just a little abstract that might lead to bigger things down the road.
Elena, you've done a lot of research on telomeres. Tell us where that stands right now in our understanding of ILD and risk. Yes, telomeres are a really really hot topic. And it's a little bit hard sometimes to really know whether senescence comes first, telomeres second, or telomeres first, senescence second, or both are happening at the same time. But there is definitely a lot of new information coming in that short telomere lengths and variants in genes that maintain the telomeres really play a big role — and not just in idiopathic pulmonary fibrosis, IPF — but we are seeing it in other types of ILD as well.
There was a study done a few years ago out of UT Southwestern where Chad Newton and others looked at how the telomere length was predicting survival, and they were looking at SARD ILD, IPF, and actually IPAF and pneumonia without immune features. They did find that those who had short telomeres tended to have more of a UIP pattern but also a lot more progression and earlier death. But the caveat is that SARD didn't have such a high prevalence of short telomeres. So it's still there — we know that there is more short telomere length in scleroderma — but perhaps it is just not as enriched sometimes as in some cohorts of less-classifiable or more idiopathic disease.
Elsewhere in the meeting — I think maybe on the roundup — Randy Kavanagh and I talked about clonal hematopoiesis being a feature that colors the story behind GCA and vasculitis. And these are looking at basically mutant clones — clonal hematopoiesis, or CHIP — which is associated with aging like telomere changes, but also associated with ILD risk and risk of relapse in vasculitis. So it looks like some of these biomarkers are making sense in that they're coming from aging, coming from breakdown, and we tend to get these diseases as we get older. It makes some sense to me.
But Janet, do you think this is going to become part of the workup? So I'm going to say yes and no. The yes is — the PPF, progressive pulmonary fibrosis, expert sites are doing it more for research. I think some of the IPF centers are doing it commercially but they don't know what to do with the results. But I think again if I have a person who has maybe just a little bit of fibrotic change and they're healthy — like they have their SARD under control — I really need the crystal ball — a decent enough biomarker that says they might progress or not — because some of them, as I say, they go under the radar screen. So the short answer is in clinical care today, no. Will we get a little biomarker panel or a big biomarker panel that is more predictive of intervening earlier? Wouldn't it be great if we got reversibility? Are we going to send these people all off for CRISPR? Probably not because it's not feasible. So bottom line is I think more will come and I think that right now it's not really too helpful for us in the clinic, but it's helpful in research and I think more ideas will come from it.
You know, I tend to be very old school on a lot of new interventions and studies and whatnot in that I like to be pragmatic. But I will say that when it comes to scary diseases — and by under the category of scary diseases, systemic sclerosis and MDA5 myositis — I would tend to be liberal in my ordering of cutting-edge diagnostic tests that can be used to prognosticate or stage, if only so that I can have an intelligent conversation with Elena Gkrouzman at the Mayo Clinic, who's going to be able to tell me what she knows about all the information I've gathered. I do that all the time with vasculitis — I call the mavens at the Cleveland Clinic — I call Janet on what to do with a scleroderma patient who is scaring me, and I don't really know what the best first or next intervention is going to be. I think that it does make sense at times to be aggressive.
So on the other hand, there's a lot of research that was shown at ACR and the question is how impactful, how much utility it has. I'll close with abstract 2882 by Vanchieri et al., which includes Jeff Sparks' group at Brigham and Mass General, and they did a sort of discovery-and-validation study on autoantibodies in patients with RA with and without ILD. They had RA controls, IPF controls, healthy controls, and they looked to see what antibodies could be used. They did a sort of wide breadth of antibodies and they found that in when they looked at all their RA-ILD cases, over three-quarters of them had at least one positive autoantibody. And they looked at rheumatoid factor IgA, IgM, CCP IgA and IgG, CarP antibodies IgG, and PAD3 IgG antibodies. So a lot more tests than I would normally get. But obviously the CCP could be driven by citrullination that you get with PAD antibodies — that could be reflective of that. Same thing for homocitrullination with CarP. And they did find that certain of these antibodies indicative of carbamylation and citrullination were very much involved in the pathogenesis of RA-ILD, suggested by both the discovery set and then validated in the validation subset.
And that's important because I think the question is — if RA is a disorder of the mucosa, right? The mucosal hypothesis of RA — that the lung is the point of attack. It's not surprising that not only will you get autoantibodies that may be pathogenic leading to the clinical state of RA, but that what goes on in the lung may be an early entry into a cascade you can't stop, which is interstitial lung disease, which is deadly in RA.
So I like the story of multiple autoantibodies showing up. But does any of this change your thinking, Elena? I guess not really. Not yet. I deal a lot with IPAF — pneumonia without autoimmune features — so I see a lot of ILD with autoantibodies and some of those autoantibodies can be really kind of non-specific and not necessarily fitting any other specific disease. And for me I guess autoantibodies have long been just a marker of some inflammation, some autoimmunity that is going on. So not too much. I will say a caveat — myositis-specific antibodies might be different — but in terms of those RA antibodies that you listed, not yet.
Yeah. I used to look at multiple autoantibodies in someone with lung disease — especially what we think is immune-mediated lung disease — as being nonsensical, because you're stimulating all those immunologically active alveoli and their macrophages to just run amok, with alpha interferon driving a lot of autoimmunity and many other signals driving autoantibody production.
Janet, would you think of these autoantibodies — the multiplicity of them — as biomarkers in RA lung? Well, they maybe are. I mean, it was a really interesting presentation and I think the bottom line is it's really important for research. Am I going to — in the next patient that I'm worried about because they're older, male, smoke, bad disease in the first 20 years before we had really good drugs or treating to target — am I going to start looking, or am I going to say you're at risk and I'm going to follow you carefully? Because we don't routinely do CarP or PAD and all that stuff. So I think it's interesting and I think it might be even somewhat mechanistic, as you mentioned, like the mucosal hypothesis — that you're breaking down a barrier possibly, etc. But I think right now for my patients with RA I am not screening everyone other than listening to the bases of the lungs, like I said earlier — listen for crackles — but I'm screening and I'm investigating wherever I think it's appropriate or if I'm kind of concerned. We had a patient today come in who had very very mild clubbing that we didn't see last time and we're going to investigate. We don't know why.
Yeah. Find the clues, chase down the clues. I want to thank our panel for an excellent discussion on a tough and very important subject of interstitial lung disease. They were out there looking at all the posters and all the oral presentations, and I think we got a glimpse of what was important from the meeting. Elena, Derek, and Janet — thanks so much. Tune in for more on these panel discussions. All right, everyone. Thank you. Thanks.
Recommended videos
-
Education/ACR/EULAR
Snippets & SNPs in ILD and Fibrosis
-
General Rheumatology
What are our goals, really, in ILD?
-
General Rheumatology
Interstitial Pneumonia with Autoimmune Features (IPAF)

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.